JNJ Stock Recent News
JNJ LATEST HEADLINES
Johnson & Johnson (NYSE:JNJ ) BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ET Company Participants John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Tim Anderson - Bank of America Tim Anderson I think we're live. Thank you for joining us.
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies, including Pfizer and Nordstrom, met the "safer" qualification with free cash flow yields exceeding dividend yields. Analysts estimate net gains of 19.58% to 41.46% for top Fortune 50 WMA companies by May 2026, with Novo Nordisk leading.
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the specific breakdown of the trade between these two countries and JNJ's relatively minor exposure to China.
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Market turmoil often triggers a rush to 'safe' assets, but I believe these moments are best for buying cyclical stocks with strong upside potential. Rather than chasing what's popular, I focus on all-weather dividend stocks, businesses built to deliver steady income through good times and bad. In this article, I present two safe standout players with tremendous turnaround potential, great dividend track records, and attractive valuations.
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.